Use of HMG-CoA reductase inhibitors for the treatment of cisplatin resistant cancer

摘要

The present invention provides a means for the treatment of cisplatin resistant cancer. Specifically, the present invention provides a cisplatin resistant cancer cytotoxic agent containing an HMG-CoA reductase inhibitor. According to the present invention, cisplatin-resistant cancer cells can be effectively damaged, so that cisplatin-resistant cancer can be treated.